RMC-0708

RMC-0708 (also known as RM-046) is a first-in-class, oral, small molecule inhibitor that selectively targets the KRASQ61H(ON) mutant protein. It is designed to drive tumor regression by inhibiting the active (GTP-bound or "ON") state of KRAS Q61H—a mutation implicated in various cancers. The drug acts as a non-covalent, mutant-selective tri-complex inhibitor and has demonstrated robust anti-tumor activity in preclinical models. Developed by Revolution Medicines, RMC-0708 validates KRASQ61H as a therapeutic target and represents an innovative approach for treating cancers driven by this specific mutation[1][2][3][9].

Other names

RMC-0708RMC0708RMC 0708RM-046RM046RM 046